Patients from 40 states & 3 countries
Our patients have traveled from around the world for our leading-edge programs, clinical trials, personalized treatment plans and quality of life and survivorship programs for both adult and pediatric brain tumor patients.
100+ physicians, researchers, scientists and staff
Our team at the Wells Center for Brain Tumor Therapy at UF includes experts in several specialties, including specialty surgical care, radiation therapy, laser ablation therapy, neuro-oncology care, genetic testing and precision medicine.
Over $10 million a year invested in research funding
From immunotherapy to chemotherapy, optune therapy and unique clinical trials, we are leading the country in searching for a cure for brain tumors.
Fast Facts
Our clinical trials portfolio includes:
- More than 40 research studies
- More than 10 Pediatric-focused studies
- Five phase-1 Trials
- First-In-Human treatments
- Investigational New Drugs developed at UF
Listed below are the clinical trials that we are currently enrolling at UF, for general questions about clinical trials please contact John Lybarger at John.Lybarger@neurosurgery.ufl.eduÂ
Featured Trial
IMPACT
Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
Subject Inclusion criteria:
- Adult
- Age: At least 18 years of age
- Newly-diagnosed de novo GBM based on the absence of previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (secondary GBM not eligible)
- Tumor must have a supratentorial componentÂ
- CD70 positive (≥20%, 1+)
- Tumor testing will be performed as part of study screening
- Pediatric
- Ages four to >18 years old
- Newly-diagnosed pHGG based on the absence of previous history of brain tumor (WHO Grade III-IV glioma) by histopathology
- CD70 positive (≥20%, 1+)
- Tumor testing will be performed as part of study screening
See full inclusion criteria and learn more about the IMPACT Clinical Trial (Link to the CT.gov https://classic.clinicaltrials.gov/ct2/show/NCT05353530)
Contact Phuong Deleyrolle to hear more about the IMPACT Clinical Trial  (phuong.deleyrolle@neurosurgery.ufl.edu)
PNOC 020
A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).
Adult Subject Inclusion Criteria:
- Age: 21 Years and older (Adult, Older Adult)
- Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
- The tumor must have a supratentorial component.
- Bone Marrow, Renal and Hepatic tests
Pediatric Subject Inclusion Criteria:
- > 3 years
- No Methylation requirement
- The Tumor must have a supratentorial component.
- Bone Marrow, Renal, and Hepatic tests
See full inclusion criteria and learn more about the PNOC 020 Clinical Trial
Contact Marcia Hodik to hear more about the PNOC 020 Clinical Trial.
Browse or search current neurosurgery clinical trials
ADAGiO
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients.
IMPACT-Adult
Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
• Adult
• Age: At least 18 years of age
• Newly-diagnosed de novo GBM based on the absence of previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (secondary GBM not eligible)
• Tumor must have a supratentorial component
• CD70 positive (≥20%, 1+)
• Tumor testing will be performed as part of study screening
IMPACT-Peds
Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
• Ages four to >18 years old
• Tumor must have a supratentorial component
• CD70 positive (≥20%, 1+)
• Tumor testing will be performed as part of study screening
• Newly-diagnosed pHGG based on the absence of previous history of brain tumor (WHO Grade III-IV glioma) by histopathology
Coordinator
MATCHPOINT
MATCHPOINT: Medulloblastoma Adoptive T cell therapy, DC vaccines, and Hematopoietic stem cells combined with immune checkPOINT blockade
Coordinator
OPTIMUS Prime
OPTIMUS PRIME: Safety and feasibility of OPTune Integrated with MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd
Trial
PBTC-053
A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma
PEACH
Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Coordinator
PNOC 019
A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
PNOC 020
A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).
Coordinator
PNOC-021
PNOC 021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
RNA Prime
RNA PRIME: RNA lipid particles targeting Pediatric Recurrent Intracranial Malignancies and other systEmic solid tumors
Coordinator